Transplant Surgery, Charité, CVK, Berlin, Germany.
Am J Transplant. 2013 Sep;13(9):2384-94. doi: 10.1111/ajt.12384. Epub 2013 Aug 5.
With excellent short-term survival in liver transplantation (LT), we now focus on long-term outcome and report the first European single-center 20-year survival data. Three hundred thirty-seven LT were performed in 313 patients (09/88-12/92). Impact on long-term outcome was studied and a comparison to life expectancy of matched normal population was performed. A detailed analysis of 20-years follow-up concerning overweight (HBMI), hypertension (HTN), diabetes (HGL), hyperlipidemia (HLIP) and moderately or severely impaired renal function (MIRF, SIRF) is presented. Patient and graft survival at 1, 10, 20 years were 88.4%, 72.7%, 52.5% and 83.7%, 64.7% and 46.6%, respectively. Excluding 1-year mortality, survival in the elderly LT recipients was similar to normal population. Primary indication (p < 0.001), age (p < 0.001), gender (p = 0.017), impaired renal function at 6 months (p < 0.001) and retransplantation (p = 0.034) had significant impact on patient survival. Recurrent disease (21.3%), infection (20.6%) and de novo malignancy (19.9%) were the most common causes of death. Prevalence of HTN (57.3-85.2%, p < 0.001), MIRF (41.8-55.2%, p = 0.01) and HBMI (33.2-45%, p = 0.014) increased throughout follow-up, while prevalence of HLIP (78.0-47.6%, p < 0.001) declined. LT has conquered many barriers to achieve these outstanding long-term results. However, much work is needed to combat recurrent disease and side effects of immunosuppression (IS).
在肝移植(LT)中取得了优异的短期存活率后,我们现在关注长期结果,并报告了首个欧洲单中心 20 年存活率数据。在 313 名患者(09/88-12/92)中进行了 337 例 LT。研究了对长期结果的影响,并与匹配的正常人群的预期寿命进行了比较。详细分析了 20 年随访中超重(HBMI)、高血压(HTN)、糖尿病(HGL)、高血脂(HLIP)和中度或严重肾功能受损(MIRF、SIRF)的情况。患者和移植物的 1 年、10 年和 20 年存活率分别为 88.4%、72.7%、52.5%和 83.7%、64.7%和 46.6%。排除 1 年死亡率后,老年 LT 受者的存活率与正常人群相似。主要适应证(p<0.001)、年龄(p<0.001)、性别(p=0.017)、6 个月时肾功能受损(p<0.001)和再次移植(p=0.034)对患者存活率有显著影响。复发性疾病(21.3%)、感染(20.6%)和新发恶性肿瘤(19.9%)是死亡的最常见原因。高血压(HTN)的患病率(57.3-85.2%,p<0.001)、中度或严重肾功能受损(MIRF)(41.8-55.2%,p=0.01)和超重(HBMI)(33.2-45%,p=0.014)在整个随访期间增加,而高血脂(HLIP)的患病率(78.0-47.6%,p<0.001)下降。LT 克服了许多障碍,取得了这些出色的长期结果。然而,仍需要做大量工作来对抗复发性疾病和免疫抑制(IS)的副作用。